← Leaderboards
W. Ray Kim
Mayo Clinic Coll Of Medicine, Rochester
$11,120,452
Attributed
$11,321,583
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,321,583 · 7
By mechanism
R01$7,488,342 · 2
U01$1,733,247 · 1
K24$627,126 · 1
K23$600,210 · 1
R21$570,961 · 1
T32$301,697 · 1
Top collaborators
- Anson W Lowe1 shared
- Eric Sibley1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Virginia M Miller$9,622,525
- Alex A Adjei$13,436,633
Others in their field
Top investigators on “Morbidity - Disease Rate”
- Marco Pahor · Wake Forest University Health Sciences$29,421,775
- A Benedict Cosimi · Massachusetts General Hospital$17,236,164
- Judith S. Currier · University Of California Los Angeles$11,229,603
- Andrea Jenay Ruff · Johns Hopkins University$10,896,035
- Lucile L Adams-Campbell · Howard University$10,384,616
- Michael K Ong · University Of California Los Angeles$9,898,332
Research focus
Morbidity - Disease RateLiver DiseasesStagingCohortPrevalenceAreaLiverRenal FunctionCause Of DeathCaringBaseMortality Vital StatisticsProspectiveClinicSerumPatient CareDiagnosisLiver TransplantationMathematical ModelNephrotoxicityFibrosisCreatinineFutureImmunosuppressive Agents
Grant awards (34)
Stratification of Non-alcoholic Fatty Liver Disease using the SAFE Score$394,215
R01 · FY2023 · DK · contact PI
Stratification of Non-alcoholic Fatty Liver Disease using the SAFE Score$394,215
R01 · FY2022 · DK · contact PI
Stratification of Non-alcoholic Fatty Liver Disease using the SAFE Score$481,685
R01 · FY2021 · DK · contact PI
Stratification of Non-alcoholic Fatty Liver Disease using the SAFE Score$471,006
R01 · FY2020 · DK · contact PI
Training grant in academic gastroenterology$301,697
T32 · FY2017 · DK · contact PI
Patient-oriented and effectiveness research in chronic liver disease$123,842
K24 · FY2016 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$468,828
R01 · FY2015 · DK · contact PI
Patient-oriented and effectiveness research in chronic liver disease$124,529
K24 · FY2015 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$544,027
R01 · FY2014 · DK · contact PI
Patient-oriented and effectiveness research in chronic liver disease$125,197
K24 · FY2014 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$529,073
R01 · FY2013 · DK · contact PI
Patient-oriented and effectiveness research in chronic liver disease$126,779
K24 · FY2013 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$637,320
R01 · FY2012 · DK · contact PI
Optimal Long-term Outcome of Chronic Hepatitis B$273,043
U01 · FY2012 · DK · contact PI
Patient-oriented and effectiveness research in chronic liver disease$126,779
K24 · FY2012 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$494,386
R01 · FY2011 · DK · contact PI
Optimal Long-term Outcome of Chronic Hepatitis B$416,786
U01 · FY2011 · DK · contact PI
L-arginine supplement for the prevention of calcineurin inhibitor nephrotoxicity$285,151
R21 · FY2011 · AT · contact PI
Models for Optimal Liver Transplant Outcomes$538,819
R01 · FY2010 · DK · contact PI
Optimal Long-term Outcome of Chronic Hepatitis B$523,159
U01 · FY2010 · DK · contact PI
L-arginine supplement for the prevention of calcineurin inhibitor nephrotoxicity$1
R21 · FY2010 · AT · contact PI
Models for Optimal Liver Transplant Outcomes$570,343
R01 · FY2009 · DK · contact PI
Optimal Long-term Outcome of Chronic Hepatitis B$363,234
U01 · FY2009 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$559,448
R01 · FY2008 · DK · contact PI
L-arginine supplement for the prevention of calcineurin inhibitor nephrotoxicity$285,809
R21 · FY2008 · AT · contact PI
Optimal Long-term Outcome of Chronic Hepatitis B$157,025
U01 · FY2008 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$583,562
R01 · FY2007 · DK · contact PI
Epidemiology and Impact of Hepatitis C in the Community$119,826
K23 · FY2007 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$413,293
R01 · FY2006 · DK · contact PI
Epidemiology and Impact of Hepatitis C in the Community$120,906
K23 · FY2006 · DK · contact PI
Models for Optimal Liver Transplant Outcomes$408,122
R01 · FY2005 · DK
Epidemiology and Impact of Hepatitis C in the Community$119,826
K23 · FY2005 · DK
Epidemiology and Impact of Hepatitis C in the Community$119,826
K23 · FY2004 · DK
Epidemiology and Impact of Hepatitis C in the Community$119,826
K23 · FY2003 · DK